Session Information
Session Title: AA 2022 Posters - Neurological Rehabilitation
Session Time: None. Available on demand.
Disclosures: Richard D. Zorowitz, MD, FAAPMR, FAHA: Ipsen Pharmaceuticals (Products/Services: Yes) (Research Grant or Support)
Background and/or Objectives: To describe real-world abobotulinumtoxinA (aboBoNT-A) injection patterns for patients presenting for treatment of lower limb spasticity.
Design: AboLiSh is a prospective, longitudinal, observational study (NCT04050527) exploring the real-world utilization and effectiveness of aboBoNT-A for lower limb spasticity.
Setting: International specialist centers across 9 countries.
Participants: Adult patients (≥18 years old) with unilateral adult lower limb spasticity and able to take ≥5 steps (with or without assistance).
Interventions: Patients are treated with aboBoNT-A in accordance with local prescribing guidelines to achieve individualized treatment goals.
Main Outcome Measures: We report key aboBoNT-A injection parameters at baseline, including muscles selected for injection, doses per muscle, and use and type of injection guidance techniques.
Results: The baseline population includes 421 adults with lower limb spasticity, from 45 sites in 9 countries (mean±SD age 53.7±13.9 years; 65.1% male). Most (96.4%) have spasticity due to acquired brain injury (stroke/trauma). The median total injected dose of aboBoNT-A was 600U [range 100-1500U], which was injected into a median of 4 muscles [1-8] with most injections given under guidance (74.0%; EMG 41.0%, electrostimulation 32.3%, ultrasound 42.9%). The most commonly injected lower limb muscles (>20% patients) were: gastrocnemius medial head (injected in 82.7% of patients, median dose 150U), gastrocnemius lateral head (71.7%, 150U), soleus (66.5%, 200U), tibialis posterior (49.6%, 150U), flexor digitorum longus (39.0%, 100U), and flexor hallucis longus (22.1%, 100U). For these muscles, use of injection guidance ranged from 71.6% for the gastrocnemius medial head to 79.9% for the flexor digitorum longus. While there was significant variation, the modal aboBoNT-A dilution was 200U/mL.
Conclusions: In these baseline analyses, six muscles were identified as being most frequently injected for lower limb spasticity. Injection practice was consistent with foot equinus and/or varus as the most common pattern of lower limb spasticity treated, consistent with a key goal of improving mobility.
Level of Evidence: Level II
To cite this abstract in AMA style:
Zorowitz RD, Esquenazi A, Ashford S, Calvi-Gries F, Maisonobe P, Jacinto J, Page S. Which Are the Most Frequently Injected Muscles in Patients Undergoing Treatment with AbobotulinumtoxinA for Lower Limb Spasticity in Routine Practice? Baseline Data from the Abolish Study [abstract]. PM R. 2022; 14(S1)(suppl 1). https://pmrjabstracts.org/abstract/which-are-the-most-frequently-injected-muscles-in-patients-undergoing-treatment-with-abobotulinumtoxina-for-lower-limb-spasticity-in-routine-practice-baseline-data-from-the-abolish-study/. Accessed September 7, 2024.« Back to AAPM&R Annual Assembly 2022
PM&R Meeting Abstracts - https://pmrjabstracts.org/abstract/which-are-the-most-frequently-injected-muscles-in-patients-undergoing-treatment-with-abobotulinumtoxina-for-lower-limb-spasticity-in-routine-practice-baseline-data-from-the-abolish-study/